Department of Ophthalmology, Peking University People's Hospital, Eye Diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing, China.
Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University, China.
Biomed Res Int. 2018 Oct 18;2018:4582816. doi: 10.1155/2018/4582816. eCollection 2018.
Mutations in the gene usually cause bestrophinopathies, such as the rare progressive diseases Best vitelliform macular dystrophy (BVMD) and autosomal recessive bestrophinopathy (ARB). This study aimed to investigate the clinical characteristics of patients with BVMD or ARB carrying mutations. A total of 12 probands including 9 patients with a clinical diagnosis of BVMD and 3 patients with a clinical diagnosis of ARB were recruited for genetics analysis. All patients underwent detailed ophthalmic examination. All coding exons of the gene were screened by PCR-based DNA sequencing. Programs of PolyPhen-2, SIFT, and MutationTaster were used to analyze the potential pathogenicity of the mutations in . In the 9 unrelated patients with BVMD, one heterozygous mutation was revealed in 8 patients and two compound heterozygous mutations in 1 patient. In the 3 unrelated patients with ARB, two compound heterozygous mutations were revealed in 2 patients and three compound heterozygous mutations in 1 patient. Molecular analyses identified a total of 15 mutations, including 3 novel mutations (c.424A>G p.S142G, c.436G>A p.A146T, and c.155T>C p.L52P). Antivascular endothelial growth factor (VEGF) drugs were given to two affected eyes, especially those also exhibiting choroidal neovascularization (CNV), and no serious adverse events occurred. Our study indicates that there is wide genotypic and phenotypic variability in patients with BVMD or ARB in China. The screening of gene is significant for the precise diagnosis of BVMD and ARB.
基因突变通常会导致 Bestrophinopathy,如罕见的进行性疾病 Best 型黄斑营养不良症(BVMD)和常染色体隐性 Bestrophinopathy(ARB)。本研究旨在探讨携带基因突变的 BVMD 或 ARB 患者的临床特征。共招募了 12 名先证者,包括 9 名临床诊断为 BVMD 的患者和 3 名临床诊断为 ARB 的患者进行基因分析。所有患者均接受了详细的眼科检查。通过基于 PCR 的 DNA 测序筛选基因的所有编码外显子。使用 PolyPhen-2、SIFT 和 MutationTaster 程序分析突变的潜在致病性。在 9 名无亲缘关系的 BVMD 患者中,8 名患者发现 1 个杂合突变,1 名患者发现 2 个复合杂合突变。在 3 名无亲缘关系的 ARB 患者中,2 名患者发现 2 个复合杂合突变,1 名患者发现 3 个复合杂合突变。分子分析共鉴定出 15 种突变,包括 3 种新突变(c.424A>G p.S142G、c.436G>A p.A146T 和 c.155T>C p.L52P)。给予 2 只受影响的眼睛抗血管内皮生长因子(VEGF)药物,特别是那些也表现出脉络膜新生血管(CNV)的眼睛,未发生严重不良反应。本研究表明,中国的 BVMD 或 ARB 患者存在广泛的基因型和表型变异性。基因的筛查对 BVMD 和 ARB 的精确诊断具有重要意义。